AUS
NZ
UK
CA
USA
IND
GSK PLC (LSE:GSK) has announced that its blood cancer medication, Blenrep (belantamab mafodotin), has been granted Breakthrough Therapy Designation (BTD) in China. This designation, awarded by the National Medical Products Administration (NMPA), is intended to accelerate the development and review of treatments that show substantial promise in improving outcomes for serious diseases.
The designation follows promising interim results from the Phase III DREAMM-7 trial, which investigated Blenrep in combination with two existing treatments. The trial highlighted significant improvements in progression-free survival for patients with relapsed or refractory multiple myeloma, a type of blood cancer. While overall survival results are still being evaluated, the trial demonstrated that Blenrep, when used with a treatment called BorDex, led to deeper and more durable responses compared to current options.
Multiple myeloma is a growing health concern in China, with approximately 30,000 new cases reported annually. The incidence and mortality rates for this disease have seen a notable increase over the past three decades, underscoring the need for more effective treatments.
GSK's Breakthrough Therapy Designation is a significant step in advancing Blenrep's availability and could potentially expedite its path to market in China. This move aligns with GSK’s commitment to addressing critical medical needs and improving patient outcomes in areas with high unmet needs.
